These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29221778)

  • 21. Dopamine D
    Rodgers HM; Lim SA; Yow J; Dinkins ML; Patton R; Clemens S; Brewer KL
    Pharmacol Biochem Behav; 2020 Jul; 194():172935. PubMed ID: 32335101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
    Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R
    Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
    Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG
    Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
    Montplaisir J; Denesle R; Petit D
    Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
    Silver N; Allen RP; Senerth J; Earley CJ
    Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).
    Winkelman JW; Johnston L
    Sleep Med; 2004 Jan; 5(1):9-14. PubMed ID: 14725821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
    Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
    J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of dopamine receptor agonists in the treatment of restless legs syndrome.
    Happe S; Trenkwalder C
    CNS Drugs; 2004; 18(1):27-36. PubMed ID: 14731057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
    Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
    Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
    Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
    Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rotigotine for restless legs syndrome.
    Davies S
    Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).
    Garcia-Borreguero D; Cano-Pumarega I; Marulanda R
    Sleep Med Rev; 2018 Oct; 41():50-60. PubMed ID: 29602660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization.
    Fiorentini C; Busi C; Gorruso E; Gotti C; Spano P; Missale C
    Mol Pharmacol; 2008 Jul; 74(1):59-69. PubMed ID: 18424554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Transdermal Rotigotine in the treatment of restless legs patients who develop augmentation of symptoms].
    Miranda C M
    Rev Med Chil; 2013 Mar; 141(3):407-8. PubMed ID: 23900336
    [No Abstract]   [Full Text] [Related]  

  • 39. C57BL/6J mice exhibit reduced dopamine D3 receptor-mediated locomotor-inhibitory function relative to DBA/2J mice.
    McNamara RK; Levant B; Taylor B; Ahlbrand R; Liu Y; Sullivan JR; Stanford K; Richtand NM
    Neuroscience; 2006 Nov; 143(1):141-53. PubMed ID: 16938406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADMET considerations for restless leg syndrome drug treatments.
    de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1247-61. PubMed ID: 22808933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.